Systolic Hypertension in the Elderly Program

Systolic Hypertension in the Elderly Program
Name	Systolic Hypertension in the Elderly Program
Acronym	SHEP
Type	Randomized controlled trial
Start	1978
Completed	1991
Location	United States
Participants	4,736
Principal investigator	Lewis H. Kuller
Sponsor	National Heart, Lung, and Blood Institute

Systolic Hypertension in the Elderly Program was a landmark randomized controlled trial that evaluated the benefits of treating isolated systolic hypertension in older adults, demonstrating reductions in stroke and cardiovascular events and influencing subsequent hypertension practice. The trial enrolled thousands of participants across multiple centers and produced findings cited by major agencies and guideline committees, reshaping care for aging populations.

Background and Rationale

The trial arose amid rising attention to cardiovascular risk in aging cohorts after observational work by figures such as Earl Sutherland, Ancel Keys, Framingham Heart Study, James F. Fries, and institutions like the National Institutes of Health, National Heart, Lung, and Blood Institute, and Johns Hopkins Hospital. Epidemiologic data from studies including the Framingham Heart Study, analyses by Maurice H. Seevers and reports from organizations such as the American Heart Association highlighted isolated systolic hypertension as a predictor of stroke and heart disease in elderly populations seen in centers like Mayo Clinic and Massachusetts General Hospital. Debates involving researchers at Harvard Medical School, Stanford University School of Medicine, and the University of California, San Francisco about risks and benefits of pharmacologic lowering of systolic pressure motivated a large randomized trial funded by federal agencies including the National Institutes of Health and overseen by steering committees with experts from Columbia University, University of Pittsburgh, and University of North Carolina at Chapel Hill.

Study Design and Methods

SHEP used a multicenter, double‑blind, placebo‑controlled randomized design enrolling 4,736 participants aged 60 years or older across clinical sites associated with universities such as University of Minnesota, University of Texas Southwestern Medical Center, and Northwestern University Feinberg School of Medicine. The trial protocol, overseen by principal investigators linked to University of Pittsburgh School of Medicine and University of Pittsburgh Medical Center, specified primary endpoints including stroke and myocardial infarction, secondary endpoints aligned with work from Doll and Hill and trial definitions used by committees including the Data and Safety Monitoring Board and international consortia influenced by the World Health Organization. Statistical methods employed were consistent with approaches used in trials at Cedars-Sinai Medical Center and analytic standards from biostatisticians at Johns Hopkins Bloomberg School of Public Health and University of Washington School of Public Health.

Interventions and Treatment Protocols

Participants were randomized to active treatment versus placebo with a stepwise antihypertensive regimen beginning with chlorthalidone and titrating agents such as atenolol or reserpine, reflecting pharmacologic knowledge from researchers at Merck & Co. laboratories and prior clinical pharmacology reports from Pfizer and academic pharmacology departments including Yale School of Medicine and Columbia University College of Physicians and Surgeons. Treatment algorithms paralleled dosing strategies discussed in symposia at American College of Physicians meetings and guidelines issued by the Joint National Committee panels, with follow-up visits conducted at centers like Vanderbilt University Medical Center and Emory University School of Medicine to monitor blood pressure targets and adherence.

Results and Outcomes

SHEP demonstrated a statistically significant reduction in stroke incidence and major cardiovascular events in the active treatment arm, with absolute and relative risk reductions emphasized in summaries by investigators associated with University of Pittsburgh, University of Minnesota, and the National Heart, Lung, and Blood Institute. Findings were presented at meetings hosted by organizations such as the American Heart Association and published in journals frequented by academics from Harvard Medical School, Stanford University, and Columbia University, influencing meta-analyses by groups at Cochrane Collaboration and reviews from the World Health Organization. The trial reported improvements in outcomes consistent with contemporaneous trials like the Hypertension Detection and Follow-Up Program and had concordance with observational analyses from the Framingham Heart Study.

Safety, Adverse Events, and Subgroup Analyses

Safety data documented adverse events including electrolyte disturbances and metabolic effects associated with thiazide diuretics, reported in safety briefs aligned with pharmacovigilance practices at Food and Drug Administration and peer discussions at American Society of Nephrology meetings. Subgroup analyses examined differential effects by age strata, sex, prior cardiovascular disease, and comorbidities, with investigators from centers such as University of California, San Diego, University of Florida, and Brigham and Women's Hospital contributing to pooled assessments and secondary publications. These analyses informed risk–benefit appraisals used by committees at National Heart, Lung, and Blood Institute and review panels convened by the Institute of Medicine.

Impact on Clinical Guidelines and Legacy Research

Results from the trial were incorporated into guideline updates by the Joint National Committee, the European Society of Cardiology, and guideline committees that included representatives from American College of Cardiology and American Heart Association, altering recommended thresholds and treatment targets for older adults in clinical practice across hospitals such as Mayo Clinic and academic centers including Johns Hopkins Hospital. The trial catalyzed subsequent research programs at institutions like University of Oxford, University of Cambridge, and networks coordinated by the World Health Organization, influencing large-scale trials of antihypertensive strategies, guideline syntheses by the Cochrane Collaboration, and health policy deliberations involving agencies such as the Centers for Disease Control and Prevention.

Category:Clinical trials Category:Cardiology Category:Hypertension